Albireo Pharma, Inc.
ALBO · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $40,579 | $8,308 | $9,636 | $12,740 |
| % Growth | 388.4% | -13.8% | -24.4% | – |
| Cost of Goods Sold | $1,356 | $0 | $2,210 | $0 |
| Gross Profit | $39,223 | $8,308 | $7,426 | $12,740 |
| % Margin | 96.7% | 100% | 77.1% | 100% |
| R&D Expenses | $82,522 | $76,777 | $45,575 | $31,732 |
| G&A Expenses | $0 | $42,448 | $22,963 | $18,061 |
| SG&A Expenses | $69,569 | $42,448 | $22,963 | $18,061 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10,617 | -$14,646 | $2,210 | $837 |
| Operating Expenses | $162,708 | $104,579 | $70,748 | $50,630 |
| Operating Income | -$123,485 | -$96,271 | -$61,112 | -$37,890 |
| % Margin | -304.3% | -1,158.8% | -634.2% | -297.4% |
| Other Income/Exp. Net | $89,455 | -$11,362 | -$1,605 | -$8,201 |
| Pre-Tax Income | -$34,030 | -$107,633 | -$62,717 | -$46,091 |
| Tax Expense | $117,319 | $11,362 | $8,987 | $20 |
| Net Income | -$151,349 | -$118,995 | -$71,704 | -$46,111 |
| % Margin | -373% | -1,432.3% | -744.1% | -361.9% |
| EPS | -7.87 | -7.45 | -5.77 | -3.94 |
| % Growth | -5.6% | -29.1% | -46.4% | – |
| EPS Diluted | -7.87 | -7.45 | -5.77 | -3.94 |
| Weighted Avg Shares Out | 19,221 | 15,983 | 12,438 | 11,703 |
| Weighted Avg Shares Out Dil | 19,221 | 15,983 | 12,438 | 11,703 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $13,932 | $11,362 | $5,296 | $0 |
| Depreciation & Amortization | $274 | $192 | $127 | $45 |
| EBITDA | -$19,824 | -$96,079 | -$57,294 | -$37,845 |
| % Margin | -48.9% | -1,156.5% | -594.6% | -297.1% |